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Abstract 
In pursue of innovation, developing countries play an increasingly relevant role for 
multinational pharmaceutical firms. Driven partly by cost considerations but also by 
some host country-specific scientific and technological factors, global drug companies 
increasingly relocate part of their drug development activities to those countries. In 
particular, expansion of clinical trials performed in some of the more advanced 
developing countries is notable over the last years. This paper critically addresses some 
of these issues with particular reference to Mexico. The latter case equally illustrates 
some challenges developing countries face to accommodate and govern local 
performance of clinical trials according to strict internationally accepted regulatory and 
ethical principles.  
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1. Introduction 
 
Recent years witness trends towards outsourcing and internationalization of clinical 
research by pharmaceutical firms; they increasingly run trials at numerous sites around 
the world. Several developing countries are emerging as relevant investigative sites. 
Although India and China appear as preferred destinations, good prospects to participate 
seem to lie ahead also for other advanced developing countries: Brazil, South Africa and 
as discussed here, Mexico. Besides large domestic markets, such countries have 
consolidated major regional manufacturing and export bases for multinational affiliates 
and some domestic firms. Moreover, they feature some country specific conditions 
shaping attractiveness of investigative sites.  
 
In this context, there is currently a debate on the ethical implications of running clinical 
trials in developing countries: are people there mere “guinea pigs” serving “selfish” 
commercial interests of pharmaceutical firms? (Schüklenk, 2000; Daikos, 2004; 
Sharma, 20004; Singh, 2007; TheLancet, 2007) Is it possible for them to promote 
orderly developments in the local market for clinical trials in order to protect 
participating local populations? Probable answers seem contingent on the countries’ 
capacity to shape suitable institutional and more precisely, regulatory structures around 
the operation of multinational firms (Dunning, 1994; Kuemmerle, 1999); in this 
particular case, pharmaceutical firms performing clinical trials.  
 
This chapter analyses recent developments in the markets for clinical trials in Mexico 
and other developing countries to illustrate: (1) some factors driving the dynamics and 
attractiveness of such countries as investigative sites; and, (2) some challenges they face 
to adjust and modernize local regulatory environments governing such activities. Are 
there any policy lessons to learn? The chapter brings together literature: on (i) 
internationalization of R&D and, (ii) ethical implications and regulation of clinical 
trials. Section 2 characterizes clinical trials within the broader innovatory process in the 
pharmaceutical industry including some determinants of their internationalization and 
location to developing countries. Section 3 looks at some regulatory challenges in 
relation to clinical trials in Mexico. Section 5 concludes.  
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2. Clinical trials: innovation and markets  
 
2.1 Pharmaceutical Innovation: clinical research in context 
 
Pharmaceutical innovation comprises four major stages (Figure 1): (1) Discovery or 
basic research1 leading to identification of new molecular targets, “New Chemical 
Entities (NCE’s),2” and pre-clinical studies3. (2) Development or clinical research 
comprising activities before and post-marketing of new drugs; (3) Regulatory processes 
of evaluation and eventual approval/rejection of development/marketing of 
pharmaceutical products and; (4) Manufacturing, marketing and product life-cycle 
support. (Achilladelis and Antonakis, 2001; McKelvey and Orsenigo, 2002; Hara, 2003; 
Styhre and Sundgren, 2003) The length and sequencing of each stage depends on legal, 
ethical, scientific and economic factors (Jungmittag, Reger et al., 2000; Gaudillière, 
2004). With regards to clinical trials, these are tests to certify efficacy, safety, overall 
socio-economic and technical viability of prospective new drugs or medical devices. 
New drug related clinical research is the more abundant, yet it includes: epidemic 
studies, life-style modifications, prognostic studies, health records, and test of non-
pharmacology related therapies (Interviews). This paper focuses on tests of 
pharmaceutical products.  
 
 
 
 
 
 
 
 
                                                     
1 Unlike previous random trial-and-error processes, modern drug development builds on more accurate 
understandings of how the body works both normally and abnormally, at its most basic level. It is 
possible to determine how prospective drugs might prevent, cure, or treat a disease. 
2 NCE’s are totally new drugs which in most cases represent significant therapeutic advances as ‘chemical 
structures never previously available to treat particular disease(s)’ (FDA) 
3 Pre-clinical studies in animals (in vivo) or other models (in silico) assess toxicity and other 
pharmacokinetic properties of prospective NCE’s before tests in humans can begin. Similar tests 
however, are performed in humans during clinical research (Zivin, 2000). 
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Figure 1 –Phases of the innovation process in the Pharmaceutical industry 
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innovation process.  
Source: Author based on information from AMIIF; Zivin, (2000); Reiss, (2000); and, Reichert, (2003)  
 
 
Clinical trials split in Phases I-IV, each of which differs in complexity regarding 
technical knowledge, infrastructure, number and profiles of people involved, regulatory 
requirements, and so on. Phase I constitutes first-time administration of NCE’s in 
humans (firstly on healthy volunteers); then, during Phase II the drug is administered to 
a small sample of volunteers featuring the target medical condition. These two Phases 
inform research questions, definition of analytical conditions and end-points4 for the 
subsequent more lengthy and massive studies in Phase III (Zivin, 2000). Post-marketing 
studies (Phase IV) provide information about the long-term effects of the new drug, 
while exploring opportunities to develop improved/new applications that extend life-
cycles of existing products. Clinical trials, particularly Phase III, account for the largest 
share of the 10-15 years required to bring a new drug to market and, a third or more of 
estimated investment, USD800-900 million (Boggs, Bayuk, et al., 1999; Maiti and 
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Raghavendra, 2007). Accordingly, speed, coordination, efficiency, accuracy and 
minimizing cost of trials are critical to reduce time-to-market, increase profits and 
enhance product quality; each day saved in development brings substantial gains in 
expected revenues for the firm.  
 
2.2 Internationalization to developing countries 
 
Seizing the global market for clinical trials is problematic as estimates of annual 
investment vary widely according to the source, between USD10-40 billion in 2006 
only (LeadDiscovery, 2006; LamtechInstitute, 2007). Alternatively one can look at the 
distribution of trials among investigative sites throughout the world. To do so, we rely 
on data about trials carried out in the US and other 153 countries and registered by the 
US Federal Drug Administration (FDA) –NIH-NLM. Additional data refer to annual 
applications for Clinical Investigators -medical researchers responsible to carry out 
clinical trials’ protocols- received by the FDA -BMIS.  
 
At the end of February, 2008, about 51 987 protocols had been or were being carried out 
in the world since 1948. Considering that many of these are performed in multiple sites 
at once, the actual number may add up to 75 9005 (Table 1). Global clinical trial 
activities record a tenfold increase since the year 2000, with a strong dynamism in those 
performed outside the US. Notably, whereas participant developing countries rose from 
34 to 93 in less than a decade, their share practically doubled over the same period. 
Similar situation occurs with Transition economies. A breakdown by main developing 
country region shows Latin America has the largest share; yet, driven by India and 
China, East and Southeast Asia has the strongest dynamism. Table 1 equally documents 
the weight Brazil, South Africa and Mexico have as investigative sites in their 
respective regions. Calculations based on NIH-NLM reveal that in 2007 more than 1.1 
million people would have participated in clinical trials in these five countries only 
(Figure 2). 
 
                                                                                                                                                           
4 End-points are ‘unambiguous results that indicate exactly what the treatment can do’, they signal 
changes in a patient’s condition ranging from healing to reductions in the progression of disease or 
whether dead rates have fallen (Zivin, 2000:73). 
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Table 1. Distribution of clinical trials by main countries and regions, 1948-2008 
 
1948-
2000 
2001-
2008 2008* 
1948-
2000 
2001-
2008 2008* 
Region per cent share of trials Participating countries 
World/1  6590 69274 75900 72 137 137
Developing  6.4 12.7 12.1 34 93 93
Transition 1.0 3.6 3.4 9 15 15
Developed 92.6 83.7 84.5 29 29 29
 per cent by main region By region  
Africa 1.2 1.9 1.9 7 37 37
   -South Africa 0.9 1.0 0.9 --- --- ---
Latin America 4.8 5.3 5.2 13 24 24
   -Brazil 0.2 1.1 1.0 --- --- ---
   -Mexico 0.0 1.0 0.9 --- --- ---
East, Southeast Asia and Pacific 0.3 4.9 4.5 9 19 19
   -China/2 0.1 2.6 2.4 --- --- ---
   -India 0.0 0.9 0.8 --- --- ---
Europe 0.9 2.5 2.3 10 11 11
Middle East 0.1 0.3 0.3 3 11 11
North Asia 0.0 0.3 0.3 1 6 6
Developed 2.0 1.5 1.6 29 29 29
   -US 64.1 37.5 39.8 --- --- ---
  --Europe 18.7 30.3 29.3 18 18 18
  --Japan 0.1 1.1 1.0 --- --- ---
Notes: *February, 28. 1/ Absolute numbers. /2 Includes Taiwan and Hong Kong. Otherwise, the share would go 
down to 0.0, 0.9 and 0.9, for each respective period. Our regional classification differs from that used in the 
original source. We rearranged following World Bank, IMF and OECD classifications. 
Source: Author with information from NIH-NLM 
 
 
Figure 2 –Number of study subjects in clinical, selected countries, 2000-2007 
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Notes: Data for China includes Hong Kong and Taiwan.  
Source: Author with data from NIH-NLM 
 
                                                                                                                                                           
5 “Double counting”, particularly in breakdowns by region is evident in the source (NIH-NLM). 
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Availability of qualified human resources is critical for the adequate performance of any 
system of innovation. Growing clinical trial activities would be hindered without the 
corresponding development of a pool of specialized personnel to carry them out. A 
positive response from developing countries would be the rise in the number of 
applications for clinical investigators to the FDA. For example, since 1997 those 
coming from Brazil, China, India, South Africa and Mexico have grown at an average 
13.5 per cent per annum (Figure 3). In 2007, applicants from these five countries 
represented 6.9 per cent of the total. However, since many such applications would 
correspond to a single individual, the dearth of well trained and experienced personnel 
remains a major shortcoming in developing countries. Concerns of future shortages of 
qualified people would be on the rise as current difficulties to find well-trained and 
experienced personnel are compounded by rather slow responses from local education 
systems (Singh, 2007; interviews). 
 
Figure 3 –Number of applications* to perform as clinical researcher, selected countries, 1997-
2007 
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Notes: *Number of times an application is presented even if by the same person; accordingly, a researcher may 
appear in the dataset more than one time. Data for China includes Hong Kong and Taiwan.  
Source: Author with data from BMIS 
 
 
2.3 What drives internationalization of clinical research? 
 
Globalization, rapid technological change, stronger competition and the development of 
pockets of scientific and technological excellence throughout the world compels 
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multinationals to continuously adjust and reorganize R&D activities both at home and 
abroad (Gassmann and von Zedwitz, 1999). Driven by both science and technology 
related and R&D cost related factors, firms may concentrate, spread or adopt a mix of 
these two strategies in pursue of R&D and innovation (Reddy, 1997, Patel and Vega, 
1999, Gassmann and von Zedtwitz 1999, Cantwell and Kosmopolou, 2001; von 
Zedtwitz and Gassmann, 2002). Different authors name distinctly observed trends or 
patterns of internationalization and globalization depending on whether they consider 
R&D-specific or R&D-external factors (Reddy, 1997; von Zedwitz and Gassmann, 
2002); motives, location characteristics, inter-temporal characteristics and modes of 
entry of FDI (Kuemmerle, 1999); degree of cooperation between individual R&D units 
(Gassmann and von Zedwitz, 1999). It is not our intention to review them here; it 
suffices to say they entail distinct interactions, conditions to participate and more 
importantly, different influences on the structure and performance of regional, sectoral 
and national systems of innovation (Dunning, 1994; Reddy, 1997; Le Bas and Sierra, 
2002; Archibugi and Pietrobelli, 2002; Chen, 2006a,b; Milstien et al., 2007).  
 
In identifying particular types of internationalization, country, industry and firms’ 
characteristics matter, it is problematic to set clear-cut distinctions at least between 
countries and industries (Dunning, 1994; Kuemmerle, 1999; von Zedwitz and 
Gassmann, 2002). Clearly however, multinational firms split research and at a larger 
extent, development, across geographical locations (von Zedwitz and Gassmann, 
2002)6. In such a way firms may tap on scientific and technical capabilities and other 
country-specific characteristics in “relevant markets” while protecting, enhancing or 
complementing the core knowledge developed at home (Kuemmerle, 1999, Patel and 
Vega, 1999; Le Bas and Sierra 2002). Host countries in turn, may serve different roles 
for multinationals overtime; they can either be a place to exploit knowledge and 
innovation produced at home or, part of complex regional and/or global innovation 
generating networks (Reddy, 1997; Dias and Bresciani, 2006).  
 
The pharmaceutical industry in particular, is one of the more globalized and compared 
to other industries, would show a more ample tendency to internationalize and 
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outsource R&D (Kuemmerle, 1999; von Zedwitz and Gassmann, 2002). The strategy 
would be supported by possibilities to include data from trials performed outside the US 
in any new drug/investigational drug application to the FDA (FDA, 2001).  
 
Since the rate at which clinical trials are conducted depends predominantly on the 
number, quality and cost of investigators and study subjects (Zivin, 200), it is critical for 
firms to enrol early and retain both these groups during drug testing and development, 
developing countries offer attractive options for this7 (Maiti and Raghavendra, 2007; 
interviews). Indeed, heterogeneous and growing populations, high prevalence of 
targeted diseases and lower research costs -even for fairly similar manpower’s quality 
and research conditions relative to developed countries8- partly explain expansion of 
clinical trials to developing countries; more and more, data from these countries support 
registration of new products in relevant markets such as the US. Relocation supports 
early positioning of potential new products in prospective markets too (PhRMA, 2006b; 
interviews). 
 
Firms would benefit from proximity and access to organizations that either shape 
demand for their products, notably drug regulatory authorities, or that create positive 
externalities for their manufacturing and research activities in host countries 
(Kuemmerle, 1999). Hence, they would prefer sites with relatively strong regulatory 
environments, swift evaluation and approval of research protocols, reduced times for 
drug registration and marketing authorizations (DiMasi, 2001; Piachaud, 2002). Host 
countries should also comply with tough international standards on Good Clinical 
Practices (GCP) and Good Laboratory Practices (GCP) respectively,9 so as to ensure 
quality and integrity of data and more importantly, to safeguard wellbeing of study 
                                                                                                                                                           
6 According to the authors, the split of Research and Development reflects the distinct nature of such 
processes in terms of knowledge requirements, infrastructures, personnel, social perception, and so on. 
7 In addition to outsourcing at home and abroad, intensive use of ICT’s –Internet, for example - to 
advertise, pre-screen and recruit study subjects complement strategies to attract them (van Brunt, 1999; 
Piachaud, 2002; Marks and Power, 2002; Lamb and Setley, 2005;TCSDD, 2007). 
8 Maiti and Raghavendra, (2007) for example report savings of 30-50 per cent in India for comparable 
clinical trials carried out in Europe or the US.  
9 Adoption of GCP’s in the post-II World War period responded to the need to protect integrity of 
subjects participating in clinical trials; key practices include informed consent and observance of ethical 
aspects of tests in humans. GLP’s in turn, refer to systems of management controls conditioning work in 
laboratories and research organizations ensuring quality, consistency, validity and reliability of test data. 
(FDA) 
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subjects. Good infrastructure and favourable research environments are critical as well. 
In what follows we illustrate some of these points with reference to Mexico.  
 
3. Clinical research in Mexico  
 
Mexico is the world’s 9th largest pharmaceutical market and the 2nd in Latin America. 
Strong dynamism reflects in retail sales in the private drug market growing at 6.0-8.0 
per cent per annum (IMS). It is a relevant manufacturing and export base to tender Latin 
America and at a lesser extent, the US, Europe and Asia (Interviews). With regards to 
clinical trials, there is a growing local activity as pharmaceutical related trials rose from 
285 protocols in 2000 to 1,360 protocols in 2007 (COFEPRIS, 2007). Data from 
Mexico-based trials would support registration of new products in the US and other 
relevant markets. Take for example, an affiliate of European origin in which local 
personnel developed a multivitamin product for people with diabetes in Mexico. 
However, as locally-performed trials suggested the product would have positive effects 
on some post-operation side-effects for cardiovascular diseases, at the time of the 
interview, the company’s headquarter was evaluating performance of clinical trials at a 
more global scale to test for an eventual new application. How can we explain this? In 
line with the discussion in Section 2.3, a number of country specific factors may be at 
stake.  
 
Mexico is the 11th most populated country in the world (World Bank); estimates for 
2007 set total population at 108.6 million, with about 43 million (~39 per cent) aged 19 
years or less (SINAIS). This is a potential market for paediatric products, offering 
opportunities to exploit well reputed and specialized research infrastructure in the area 
(Castellanos and Chiprut, 2002; LamtechInstitute, 2007; Interviews). Agglomeration of 
about 37.6 per cent of the population in Mexico City, her two largest neighbouring 
states, Estado de Mexico and Puebla, and in the industrial states of Jalisco and Nuevo 
León, coincides with concentration of some of the country’s largest public health 
premises, many of the most modern health related education and research facilities, and 
location of most local and foreign pharmaceutical firms in the country (CANIFARMA; 
Dussel, 1999; CCINSHAE). 
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Local demographics and epidemics lead to a mix of diseases characteristic of 
developing countries but also of more developed ones –Table 2 and SS, (2005). 
Urbanization, augmented life-expectancy at birth and improved sanitary conditions 
imply that although poverty related diseases such as Gastrointestinal and Respiratory 
infections or Malnutrition, are now in check or slightly decreasing, they persist among 
main causes of dead, particularly among children and in highly impoverished regions 
(SS, 2005). In contrast, chronic illnesses and other associated with metabolism and age 
have gained prevalence. Nowadays, “life-style” diseases such as Diabetes and Ischemia 
account for nearly a quarter of dead rates per 100 000 people; Mexico is expected to 
host one of the largest diabetic populations by 2025 (Kuri, Vargas et al., 2001). 
Shrinking natality rates, from 34.7/1000 in 1980 to 18.6/1000 in 2007, accompany a 
smooth demographic transition with the share of elderly people (65+ years old) 
increasing from 4.3 per cent to 5.5 per cent over the same period (Calderón, 2007). This 
raises expectations of growing, multiple and longer lasting future drug intakes (Kuri, 
Vargas et al., 2001; SS, 2005).  
 
Table 2 – Mexico: Main causes of dead, 2000-20051/  
Item 2000 2005 
Diabetes mellitus 10.7 13.6 
Ischemic and related heart diseases 10.1 10.8 
Cirrhosis and other chronic affections of the liver 5.8 5.6 
Brain vascular diseases 5.8 5.5 
Malign Tumours 5.5 5.3 
Lung obstructive chronic disease  3.7 4.1 
Diseases related to prenatal period  4.5 3.3 
Acute low respiratory infections  3.3 3.0 
Hypertension  2.2 2.6 
Nefresie & related 2.3 2.3 
Malnutrition  2.0 1.7 
HIV/AIDS 1.0 0.9 
Gastrointestinal infections  1.2 0.9 
Notes: 1/ Percentage of total dead ratios per 100,000 inhabitants 
Source: (SINAIS) 
 
 
At least compared to other Latin American countries, Mexico has a fairly strong public 
healthcare system that next to large population coverage, hosts some of the country’s 
more advanced health research capabilities (SS, 2005). Instituto Mexicano del Seguro 
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Social (IMSS) and Instituto de Seguridad y Servicios Sociales para los Trabajadores del 
Estado (ISSSTE) are the largest public medicare organizations with about 61 million 
affiliates (INEGI). Other relevant public organizations include the National Health 
Institutes (NHI’s) featuring ample capacity to perform clinical and some basic research, 
together with highly specialized health-assistance and training across 12 different 
therapeutic areas (CCINSHAE). Complement the sector a number of public hospitals 
and universities throughout the country. Linking to these public organizations saves 
firms the need to create specialized centres as required by Mexican authorities to 
perform clinical trials; more importantly, they grant access to huge and captive 
populations under fairly standardized research conditions (Interviews).  
 
3.1 The institutional environment underpinning clinical trials 
 
This paper enquires about the extent developing countries may be able to promote 
orderly developments in their local markets for clinical trials. Available literature 
suggests such goal is contingent on their ability to adopt proactive policy stances 
towards operation of multinational firms (Dunning, 1994; Archibugi and Pietrobelli, 
2003, Meyers, 2006; Chen, 2007). Following Dunning (1994), influences from public 
policy may either be direct -through funding and regulating R&D activities; or indirect 
by influencing the overall environment in which firms undertake innovation10. 
Regarding the latter influences, the current debate on the ethical implications associated 
with clinical trials hints at, among others, two interrelated areas relevant for policy 
intervention: (1) characteristics of the regulatory environment and, (2) the structure and 
functioning of mechanisms responsible to evaluate and monitor clinical trials (Drews, 
2000; Zivin, 2000; Castellanos and Chiprut, 2002; Fleck, 2004; Kermani, 2006; 
Lombera, 2006; Meyers, 2006; PhRMA, 2006a; Valdez-Martinez, Turnbull et al., 2006; 
Maiti and Raghavendra, 2007). These areas highlight some minimum conditions 
increasing the likelihood that local performance of clinical trials meets international 
standards about protection of study subjects, while promoting adequate interactions 
between local agents and multinational firms.  
 
                                                     
10 Until recently India banned the performance of clinical trials within its territory before similar trials had 
being carried out elsewhere already (Kermani, 2006). 
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3.1.1 Regulatory Issues 
 
Relative strength and compliance with regulatory frameworks and internationally 
accepted standards condition attractiveness of investigative sites. In Mexico, the 
regulatory authority is the Comisión Federal para la Protección contra Riesgos 
Sanitarios (COFEPRIS). Created in 2001 COFEPRIS institutionalized efforts to 
integrate, simplify and homogenize, within a single government organization, regulation 
on sanitary and related risks; items under scrutiny include pharmaceutical products but 
also basic sanitation, environmental risks, publicity on health, food and related products 
and so on (Enríquez, 2006). Regarding clinical trials, COFEPRIS has strengthened and 
increased transparency of the regulation, yet governance of trials features shortcomings 
prone to holdback their adequate development in the future (Enríquez, 2006; 
LamtechInstitute, 2007).  
 
Pending in the agenda is modernization of the regulatory framework, notably in relation 
to research. The current framework rests on The General Health Act (Ley General de 
Salud), and the associated Bill on Health Research (Reglamento de la Ley General de 
Salud en material de Investigación) dating back to 1984 and 1987, respectively (SS, 
1984 and 1987). These documents specify the steps and conditions necessary to perform 
clinical trials in Mexico. Both of them however, were conceived when such activities 
were relatively limited in the country; consequently, current guidelines are rather 
general, weaker compared to current industry standard practices -e.g. International 
Conference on Harmonization (ICH); and somehow inadequate to tackle challenges 
resulting from an expanding market (LamtechInstitute, 2007; interviews). Generality 
means the need to harmonize research, clinical and laboratory procedures throughout 
the country too. Initiatives for a Mexican Norm on Clinical Research thereby 
procedures meet highest standards agreed upon by all relevant parties need to progress 
at a greater rate (Interviews).  
 
COFEPRIS is responsible to approve and monitor clinical trials according to tight legal, 
safety, technical, ethical and other requirements set in current legislations. The agency 
however, is able only to partially fulfil the task; gaps persist in monitoring work in 
progress (Interviews). This is an issue of equal concern in India where notwithstanding 
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improved regulation of the industry, weak enforcement remains an item (Singh, 2007). 
Regulatory agencies in both countries suffer from a dearth of well trained and 
experienced personnel, financial resources and infrastructure to carry out monitoring. In 
Mexico, poor remunerations and salaries compound the picture (Interview). Mexican 
officers would lack full awareness and hands-on experience conducting clinical trials; 
learning processes would run parallel to actual performance of supervisory duties 
(Interviews). Accordingly, COFEPRIS often has to lean on “experts” from hospitals, 
research centres, universities and the industry itself to conform supervisory and 
monitoring teams (Interviews). Authorities would avoid conflicts of interest or 
inappropriate behaviours by requesting “blind” evaluations, leaving actual decision-
making on ethics committees (Interviews). The extent this practice rules out conflicts of 
interest and other problems calls for further study as, in line with the discussion in 
Section 3.1.2, major shortcomings remain in the operation of such committees. In any 
case, disappointment with an agency expected to stand as tall as the FDA but that 
instead, remains poorly empowered and financially endowed is clear (Interviews).  
 
Steps towards improving the regulatory framework in Mexico include recent creation of 
a permanent Pharmacovigilance programme and enactment of a Mexican Norm on the 
matter (Becerril, 2006). Pharmacovigilance in Mexico is therefore divided in: (1) Early 
Pharmacovigilance: mandatory by Law, it requires watching for any sanitary risk 
arizing during the first two years of commercialization of a new drug; and, (2) Intensive 
Pharmacovigilance that considers specific tests of particular features of a drug after 
commercialization, thereby requiring more active stances by firms. Requests for specific 
studies are expected to warn early on any sanitary risks associated with trials and 
consumption of pharmaceutical products. In addition, and mirroring similar experiences 
in India11, the Norm induces firms and research organizations to agree on who takes 
responsibility to notify COFEPRIS of any major sanitary risk occurring during clinical 
trials either at home or abroad (LamtechInstitute, 2007).  
 
A final none the least important aspect relates to dissemination of detailed and accurate 
information about clinical trials, this is critical to prevent potential volunteer study 
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subjects about the pros and cons of taking part in a given study; such is the essence of 
informed consent (PhRma, 2006a). In Mexico, lack of data or at least readily available 
access to them is regrettable especially considering that, as Section 2.2 documents, 
strong regulatory agencies may induce firms to provide some minimum information 
about their activities12. Better understanding of market dynamics would begin by 
solving this basic but critical statistical gap. COFEPRIS is developing an ad hoc 
database containing all research protocols in the country (Interviews); the concrete 
impact of the initiative is yet to be seen. 
 
3.1.2 Ethics Committees 
 
According to internationally accepted standards, performance of clinical trials is 
contingent on approval and close monitoring by ad hoc, independent bodies known as 
ethics committees or Institutional Review Boards13. This would explain the significant 
increase in the number of such committees throughout the world, and in particular, in 
the countries included in this study (Figure 4). In Mexico, conformation and operation 
of IRB’s, particularly within large organizations, follows paradigms set by the FDA14 
(Castellanos and Chiprut, 2002). In practice however, evidence is rather mixed about 
compliance with accepted principles of operation. In line with a study by Valdez-
Martinez, Turnbull et al., (2006) about the functioning IRB’s at IMSS -the most 
important locus for clinical trials in Mexico-, we found problems derived from the 
dearth of people with sufficient knowledge and experience to integrate the committees 
(Interviews). Responsibility to ethically evaluate protocols would often fall onto “key” 
persons -the Dean of the teaching program or the Service Head at the host organization, 
for example (Interviews). To the extent that such characters may frequently act as 
Principal Researchers -those responsible to lead the research teams conducting a trial in 
                                                                                                                                                           
11 According to (Maiti and Raghavendra, 2007), amendments made in 2005 to the Schedule Y of Drugs 
and Cosmetic Act 1945 in India, made reporting duties ‘clearer and unambiguous’ for firms. 
12 I requested COFEPRIS official data about the market for clinical trials in Mexico, the response was that 
such detailed information is nonexistent COFEPRIS (2007). 
13 Following US paradigms, ‘institutional review board/independent ethics committees (IRB/IEC)’ are a 
group of people formally designated to approve, monitor, and review biomedical and behavioural 
research involving humans with the aim to protect the rights and welfare of study subjects (FDA). 
14 Ideally, a minimum of 5 persons should integrate the Committee, with at least one independent from 
the host organization and one a member of the civil society in a non-scientific area (usually from a 
religious community or minority group) 
 
 
19
those host organization- the risks of potential conflicts of interests, insufficient 
transparency and objectivity in decision making seems high. This is relevant as 
COFEPRIS’ lack of resources and expertise undermines her capacity to ensure that 
protocols are evaluated and carried out according to proper ethical and other relevant 
standards. Enforcement of existing legislation is a real challenge (Interviews).  
 
Figure 4 –Number of applications*to the FDA by Institutional Review Boards, selected 
countries, 1997-2007 
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Deficient conformation of IRB’s would slow evaluation of new protocol applications 
too. Waiting times depend on the institution, type and number of protocols. 
Bureaucratic procedures, lack of coordination, duplication of responsibilities and even 
contradictory decision-making, particularly within large organizations, complicate 
operation of IRB’s (Interviews). Although approval times would in general, mirror that 
of developed countries (Castellanos and Chiprut, 2002); sometimes they may take up to 
3 months to emit their judgment (Interviews). Speeding up evaluation processes is 
critical as overall waiting times for regulatory approval in Mexico -including ethical 
evaluations, import licenses for investigational drugs, customs paperwork and logistics, 
and so on (Lamb and Setley, 2005)- may add-up up to 9 months (Interviews). Similar 
processes may take about 3 months in most Western European countries (BMI, 2006). 
Times for regulatory approval in Mexico would be more competitive however, 
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compared to China where this may take up to one year (Lamb and Setley, 2005). 
Industry’s proposals for the creation of ad hoc independent evaluation committees to 
compensate for the absence of IRB’s in some Mexican organizations, financed by the 
industry and actively involving regulatory authorities are currently under debate; the 
process seems to progress rather slowly, though. (Interviews)  
 
4. Concluding remarks  
 
This chapter explored recent developments in the market for clinical trials in Mexico 
and other developing countries. Hence, we illustrated a series of country specific 
characteristics underpinning attractiveness of those countries to host clinical trials; 
demographic, commercial, regulatory and, R&D related factors became much 
intertwined. From this perspective, a bunch of advanced developing countries would 
have interesting potential to continue increasing their presence as investigative sites. 
After all, multinationals would somehow complement their already established regional 
split of operations.  
 
A more relevant conclusion however, is that a number of ethical considerations call for 
a more proactive stance from developing countries vis-à-vis the activities of 
multinational firms. More specifically, they need to address important bottlenecks 
characterizing the overall institutional and regulatory environments underpinning local 
conduction of clinical research. Weak enforcement of inadequate and out of date 
regulations, alternatively slow or incomplete processes of reform and modernization of 
such frameworks supports concerns about the extent potential benefits may outperform 
the inherent risks faced by local populations participating in clinical trials. Creation of 
ad hoc regulatory agencies is insufficient if they are not properly endowed and 
empowered.  
 
Taping on local healthcare providers and health related education and research 
organizations with experience conducting clinical trials sponsored by multinational 
firms would assist to improve the structure and coordinating powers of regulatory 
agencies. For example, they could provide more adequate flows of qualified and 
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experienced manpower to meet demands from rising clinical trial activities. Strong 
regulatory agencies in turn, seem instrumental to shape and operate research systems 
meeting internationally accepted ethical and related standards. At a more basic level, 
stronger commitment of regulatory agencies to gather and make publicly available 
information about trials taking place in their circumscription would help to improve our 
understanding of the socioeconomic factors driving internationalization of clinical trials 
and their corresponding implications on developing countries.  
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Annex: Methodology and data sources 
 
This paper builds on both primary and secondary data sources. Primary data were 
gathered through semi-structured interviews carried out during fieldwork in Mexico 
between February-August 2007. Informants included people from multinational 
affiliates and Mexican pharmaceutical firms–General Directors, Medical Directors, 
Human Resource Managers, R&D Heads, Development analysts- and, representatives 
from the main local Trade Organizations CANIFARMA and AMIIF –these include 
mostly multinational affiliates accounting for 85 per cent or more worth of the local 
private market (Hernandez, 2007 and interviews). We also interviewed people from the 
Mexican regulatory agency, COFEPRIS, and the coordinating body of the public health 
and research centres hosting most clinical research protocols in Mexico (CCINSHAE). 
Interviews took an hour long on average and in most cases were audio-taped and fully 
transcribed afterwards. For reasons of an explicit commitment to confidentiality, 
identity of informants and participating firms remains anonymous.  
 
Secondary sources of information included presentations and other documentation from 
industry experts, scholars and public officers. Statistical data came from:  
 
 
 
25
(1) ClinicalTrials.gov, online database with information about the number, distribution 
and some general characteristics of clinical trials carried out in the US and other 153 
countries. Data in this paper was last accessed on February 28th, 2008. Then, there were 
52,006 records, of which 51,987 complete. We aggregated the data in order to 
distinguish between developed and developing regions, following classifications by the 
World Bank, the IMF and the OECD.  
 
(2) The Bioresearch Monitoring Information System (BMIS) provides information 
submitted to FDA about clinical investigators, contract research organizations and 
institutional review boards involved in conduction of Investigational New Drug (IND) 
studies with human investigational drugs. The data contains a separate entry for each 
time an investigator, CRO or IRB is identified in a new submission, hence, multiple 
entries are possible for single individuals or organizations. Our data correspond to the 
latest available version: 11 January, 2008.  
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